// App-Quantinova.ai

248 : Sustained improvements in disease activity for up to two-years with ixekizumab in patients with active psoriatic arthritis who were either biologic-naïve or with previous inadequate response to tumour necrosis factor inhibitor therapy

Researchers

Presenter

  • Deepak R Jadon

Principal Investigators

  • Mani Haschemi Nassab

  • Katrien Van Beneden

  • Georg Pum

  • Andrew J Bradley

Medical Centers

  • Department of Medicine, University of Cambridge, Cambridge, UNITED KINGDOM

  • Medical Affairs, Eli Lilly S.A., Vernier, SWITZERLAND

  • Medical Affairs, S.A. Eli-Lilly Benelux N.V., Brussels, BELGIUM

  • Medical Affairs, Eli Lilly GmbH, Vienna, AUSTRIA

  • Medical Affairs, Lilly UK, Basingstoke, UNITED KINGDOM

Locations

  • United Kingdom

  • Switzerland

  • Belgium

  • Austria

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriatic arthritis

  • Dactylitis

  • Inflammatory Arthritis

  • Psoriasis

Biomarkers

  • Malondialdehyde

  • Albumin/creatinine

Drug/Treatment

  • Adalimumab

  • LY2439821

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved